Caxton Associates (UK)’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-250,000
Closed -$26.3M 923
2025
Q4
$26.3M Buy
250,000
+189,055
+310% +$17.7M 0.52% 30
2025
Q3
$5.12M Buy
60,945
+21,524
+55% +$1.77M 0.12% 67
2025
Q2
$3.12M Buy
39,421
+7,458
+23% +$593K 0.08% 129
2025
Q1
$2.87M Buy
+31,963
New +$2.98M 0.1% 97

Other funds holding MRK

Caxton Associates (UK)'s MRK Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Merck (MRK) in Q1 2026, closing a stake of 250,000 shares — an estimated $26.3M sold.

Caxton Associates (UK) first reported a position in MRK in Q1 2025 and held it in 4 quarters. The position peaked at $26.3M in Q4 2025. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Merck position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 250,000 Merck shares in Q1 2026, an estimated $26.3M.
  • Caxton Associates (UK) first reported a position in Merck in Q1 2025 and held it in 4 quarters.
  • Caxton Associates (UK)'s Merck position peaked at $26.3M in Q4 2025.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.